Casdin Partners Master Fund, L Buys 500,000 Shares of Standard BioTools Inc. (NASDAQ:LAB) Stock

Posted by Chris Copeland on Aug 16th, 2024

Standard BioTools Inc. (NASDAQ:LAB – Get Free Report) Director Casdin Partners Master Fund, L bought 500,000 shares of the stock in a transaction on Monday, August 12th. The shares were acquired at an average cost of $1.64 per share, with a total value of $820,000.00. Following the purchase, the director now owns 50,025,821 shares of the company’s stock, valued at approximately $82,042,346.44. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Casdin Partners Master Fund, L also recently made the following trade(s):

On Friday, August 9th, Casdin Partners Master Fund, L purchased 525,408 shares of Standard BioTools stock. The shares were bought at an average cost of $1.61 per share, for a total transaction of $845,906.88.
On Wednesday, August 7th, Casdin Partners Master Fund, L bought 500,000 shares of Standard BioTools stock. The stock was bought at an average price of $1.57 per share, for a total transaction of $785,000.00.
On Friday, August 2nd, Casdin Partners Master Fund, L purchased 1,000,000 shares of Standard BioTools stock. The shares were bought at an average price of $1.63 per share, with a total value of $1,630,000.00.
On Monday, August 5th, Casdin Partners Master Fund, L acquired 200,000 shares of Standard BioTools stock. The shares were purchased at an average cost of $1.58 per share, for a total transaction of $316,000.00.
On Wednesday, May 22nd, Casdin Partners Master Fund, L bought 150,000 shares of Standard BioTools stock. The stock was purchased at an average cost of $2.58 per share, with a total value of $387,000.00.
On Monday, May 20th, Casdin Partners Master Fund, L purchased 100,000 shares of Standard BioTools stock. The shares were purchased at an average cost of $2.58 per share, for a total transaction of $258,000.00.
On Friday, May 17th, Casdin Partners Master Fund, L acquired 352,072 shares of Standard BioTools stock. The stock was purchased at an average cost of $2.56 per share, with a total value of $901,304.32.
On Wednesday, May 15th, Casdin Partners Master Fund, L bought 500,000 shares of Standard BioTools stock. The shares were acquired at an average price of $2.57 per share, for a total transaction of $1,285,000.00.

Standard BioTools Trading Up 16.1 %

NASDAQ LAB opened at $1.80 on Friday. The firm has a market capitalization of $666.76 million, a PE ratio of -1.72 and a beta of 1.67. The business’s 50-day moving average price is $1.98 and its two-hundred day moving average price is $2.34. Standard BioTools Inc. has a 12 month low of $1.21 and a 12 month high of $3.16.

Analyst Ratings Changes

Separately, TD Cowen dropped their price target on shares of Standard BioTools from $3.50 to $2.75 and set a “buy” rating for the company in a research note on Thursday, August 1st.

View Our Latest Stock Report on LAB

Institutional Trading of Standard BioTools

Several institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its holdings in Standard BioTools by 215.3% during the 1st quarter. Vanguard Group Inc. now owns 13,034,043 shares of the company’s stock worth $35,322,000 after purchasing an additional 8,900,104 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. acquired a new position in Standard BioTools in the first quarter valued at $23,993,000. Nikko Asset Management Americas Inc. bought a new stake in Standard BioTools during the first quarter valued at $23,993,000. Nan Fung Group Holdings Ltd acquired a new stake in Standard BioTools during the 1st quarter worth about $5,103,000. Finally, Magnetar Financial LLC bought a new position in shares of Standard BioTools in the 1st quarter worth about $4,107,000. 53.74% of the stock is currently owned by institutional investors.

About Standard BioTools

(Get Free Report)

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.